NIFTY 50

Biocon Q4FY21 today: Here’s what to expect

Updated : April 28, 2021 14:39:39 IST

Biocon to come out with its numbers today and revenue growth is estimated to grow around 29 percent, EBITDA up around 50 per cent plus, margins 23.7 percent and profit of around Rs 206 crore.

This time the biosimilar business is expected to see some amount of sequential momentum and as the COVID-19 situation is normalising a bit in the US.

However, two things to watch out for in the biosimilar business is the pricing pressure and the market share increase in drug such as insulin glargine.

Watch the accompanying video of CNBC-TV18’s Ekta Batra for more details.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you